<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077116</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06013</org_study_id>
    <secondary_id>EORTC-06013</secondary_id>
    <nct_id>NCT00077116</nct_id>
  </id_info>
  <brief_title>Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome</brief_title>
  <official_title>Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different&#xD;
      ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies,&#xD;
      such as gemtuzumab ozogamicin, can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells. Giving monoclonal antibody&#xD;
      therapy together with chemotherapy may kill more cancer cells. Giving healthy stem cells from&#xD;
      a donor whose blood closely resembles the patient's blood will help the patient's bone marrow&#xD;
      make new stem cells that become red blood cells, white blood cells, and platelets.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving idarubicin and cytarabine together&#xD;
      with gemtuzumab ozogamicin works in treating patients with previously untreated high-risk&#xD;
      myelodysplastic syndrome or acute myeloid leukemia secondary to myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of combining gemtuzumab ozogamicin with idarubicin and&#xD;
           cytarabine with or without cyclophosphamide with total body irradiation vs busulfan&#xD;
           followed by allogeneic stem cell transplantation in patients with previously untreated&#xD;
           high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antileukemic/anti-MDS activity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the hepatotoxicity of this regimen, in terms of veno-occlusive disease, in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the severity of pancytopenia and duration of recovery in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group 1 (for patients with no HLA-matched sibling donor): Patients receive&#xD;
           remission-induction chemotherapy comprising idarubicin IV over 5 minutes on days 1, 3,&#xD;
           and 5; cytarabine IV continuously over 24 hours on days 1-10; and gemtuzumab ozogamicin&#xD;
           IV over 2 hours on day 7. Treatment continues for a second course in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Group 2 (for patients with an HLA-matched sibling donor): Patients are randomized to 1&#xD;
           of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive myeloablative consolidation chemotherapy comprising&#xD;
                cyclophosphamide on days -6 and -5 and total body irradiation twice daily on days&#xD;
                -4 to -2.&#xD;
&#xD;
             -  Arm II: Patients receive myeloablative consolidation chemotherapy comprising&#xD;
                busulfan on days -8 to -5 and cyclophosphamide on days -4 and -3.&#xD;
&#xD;
      Patients in both arms may alternatively undergo T-cell depletion and/or a reduced-intensity&#xD;
      conditioning regimen.&#xD;
&#xD;
      Approximately 4-8 weeks after completion of consolidation chemotherapy, all patients in group&#xD;
      2 undergo allogeneic bone marrow transplantation or allogeneic peripheral blood stem cell&#xD;
      transplantation. Patients in group 2 then proceed to remission-induction chemotherapy as in&#xD;
      group 1.&#xD;
&#xD;
      Patients achieving complete remission are recommended for consolidation therapy off study.&#xD;
&#xD;
      Patients are followed monthly for 6 months, every 2 months for 6 months, and then every 3&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study within 10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete remission (CR) or complete remission with incomplete recovery of platelets (CRp) as measured by Cheson response criteria after the start of treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe toxicity after the start of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival from CR/CRp</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pancytopenia and duration of recovery in patients who reached CR/CRp after the start of treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  High-risk myelodysplastic syndromes (MDS), including any of the following:&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB) with &gt; 10% blast cells in the&#xD;
                       bone marrow&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Other forms of MDS with multiple (3 or more) chromosomal abnormalities or&#xD;
                       chromosome 7 abnormalities AND/OR profound cytopenias, defined as neutrophil&#xD;
                       count &lt; 500/mm^3 and/or platelet count &lt; 20,000/mm^3&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia with &gt; 5% blast cells in the bone marrow&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia with neutrophil count &gt; 16,000/mm^3 OR&#xD;
                       monocyte count &gt; 2,600/mm^3&#xD;
&#xD;
               -  Secondary acute myeloid leukemia supervening after overt MDS of more than 6&#xD;
                  months in duration&#xD;
&#xD;
          -  Patients with or without an HLA-identical sibling&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe cardiovascular disease&#xD;
&#xD;
          -  No arrhythmias requiring chronic treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic ischemic heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe lung disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No other concurrent malignant disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No history of alcohol abuse (i.e., averaged less than 5 alcoholic consumptions daily&#xD;
             for the past year)&#xD;
&#xD;
          -  No concurrent severe neurological or psychiatric disease&#xD;
&#xD;
          -  No other psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 6 weeks since prior growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior intensive chemotherapy&#xD;
&#xD;
          -  More than 6 weeks since prior low-dose chemotherapy or hydroxyurea&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 6 weeks since prior immunosuppressants&#xD;
&#xD;
          -  No prior participation in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo De Witte, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis - Roeselaere.</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

